Tracleer® (bosentan)
Tracleer® (bosentan) is an oral dual endothelin receptor antagonist. Tracleer is the only oral PAH therapy with an established safety and tolerability profile in more than 80,000 patients worldwide.
Veletri® (Epoprostenol for Injection)
Veletri® (Epoprostenol for Injection) is intravenous prostacyclin. Unlike other epoprostenol formulations approved for PAH, Veletri® is stable at room temperature (77 F, 25 C) for up to 48 hours when administered immediately upon reconstitution and dilution, making the use of frozen gel packs unnecessary.
Ventavis® (iloprost)
Ventavis® (inhaled iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclin (PGI2) – a naturally occurring molecule that causes blood vessels to dilate, limits cellular hypertrophy, and inhibits platelet aggregation.
Zavesca® (miglustat)
Miglustat, the active ingredient of Zavesca®, is an orally available molecule with a large volume of distribution, which was developed for the treatment of type 1 Gaucher disease (GD1).
